What does Novavax, Inc. do?
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license…
What is Novavax, Inc.'s P/E and P/B ratio?
Novavax, Inc. has a P/E ratio of -6.3 and a P/B ratio of -8.64.
What is Novavax, Inc.'s debt-to-equity ratio?
Novavax, Inc. has a debt-to-equity ratio of -1.95.
How much does Novavax, Inc. owe compared with what it owns?
Novavax, Inc. owes $1.20 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Novavax, Inc.'s Positivity rank?
Novavax, Inc. is ranked #6,574 of 6,775 companies globally and #3,817 of 4,000 in United States on PositoAI, with a Positivity Score of -26,103.
Does Novavax, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Novavax, Inc. has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 3/10 points): Material write-down of assets (8-K Item 2.06).
Where can I read the latest news about Novavax, Inc.?
Recent headlines about Novavax, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Novavax, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Novavax, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.